NASDAQ$SRDX
Surmodics Inc · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
Surmodics reported strong Q4 2024 financial results with revenue growth and advancements in medical device segment.
Surmodics reported a 19% year-over-year increase in total revenue for Q4 2024, driven by strong performance in the Medical Device segment. The company's GAAP net loss was $(3.4) million, while adjusted EBITDA reached $4.4 million.
- Total revenue increased by 19% year-over-year to $33.2 million.
- Medical Device revenue grew by 22% to $25.8 million, driven by vascular interventional products and performance coating reagents.
- GAAP net loss was $(3.4) million, compared to net income of $6.7 million in the prior-year period.
- Adjusted EBITDA was $4.4 million, compared to $1.7 million in the prior-year period.
Headline financials
Revenue & EPS history
Surmodics · Revenue · Quarterly
$33.2M
Revenue by segment
Surmodics · $28M total across 2 segments · Q4 2023
- Medical Device$21M+7.9%75.2%
- In Vitro Diagnostics$6.93M+6.8%24.8%
Forward guidance
Surmodics is not introducing financial guidance for fiscal year 2025 due to the pending acquisition by GTCR.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+3.0%
Avg return
5 days after
+6.9%
Avg return
30 days after
59%
37 / 63 earnings
Positive
+34.5%
Q2 2024
Best reaction
-13.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.6% | +8.5% | -8.0% | |
| Q2 2025 | -1.5% | +2.5% | +7.6% | |
| Q1 2025 | -4.1% | -4.5% | -7.3% | |
| Q4 2024 | +2.0% | +2.3% | +6.2% | |
| Q3 2024 | -0.5% | -1.2% | -4.5% | |
| Q2 2024 | +34.5% | +26.5% | +64.1% | |
| Q1 2024 | -9.8% | -13.0% | -9.6% | |
| Q4 2023 | +1.0% | — | — | |
| Q3 2023 | +4.7% | — | — | |
| Q2 2023 | -2.4% | — | — | |
| Q1 2023 | +4.1% | — | — | |
| Q4 2022 | -3.0% | — | — | |
| Q3 2022 | -7.8% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q1 2022 | -11.0% | — | — | |
| Q4 2021 | -11.4% | — | — | |
| Q3 2021 | +3.7% | — | — | |
| Q2 2021 | -5.4% | — | — | |
| Q1 2021 | +15.1% | — | — | |
| Q4 2020 | -2.1% | — | — | |
| Q3 2020 | +0.5% | — | — | |
| Q2 2020 | +3.4% | — | — | |
| Q1 2020 | +6.6% | — | — | |
| Q4 2019 | -13.1% | — | — | |
| Q3 2019 | +13.7% | — | — | |
| Q2 2019 | +0.6% | — | — | |
| Q1 2019 | +17.0% | — | — | |
| Q4 2018 | -11.5% | — | — | |
| Q3 2018 | +11.2% | — | — | |
| Q2 2018 | +7.2% | — | — | |
| Q1 2018 | -0.4% | — | — | |
| Q4 2017 | +0.2% | — | — | |
| Q3 2017 | +1.8% | — | — | |
| Q2 2017 | -7.9% | — | — | |
| Q1 2017 | +1.4% | — | — | |
| Q4 2016 | -6.2% | — | — | |
| Q3 2016 | +8.9% | — | — | |
| Q2 2016 | +14.8% | — | — | |
| Q1 2016 | +8.3% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | +9.8% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +3.6% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -4.6% | — | — | |
| Q1 2014 | +7.8% | — | — | |
| Q4 2013 | -3.6% | — | — | |
| Q3 2013 | +10.6% | — | — | |
| Q2 2013 | -6.9% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +10.0% | — | — | |
| Q2 2012 | -1.8% | — | — | |
| Q1 2011 | -1.4% | — | — | |
| Q1 2012 | -1.0% | — | — | |
| Q4 2011 | +1.6% | — | — | |
| Q4 2009 | +1.6% | — | — | |
| Q2 2011 | +1.6% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q4 2010 | +1.3% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2010 | +1.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro